Research from Journal of Clinical Oncology found that vitamin D deficiency may impair the efficacy of treatment and outcome of patients with diffuse large B-cell lymphoma.
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, a cancer that affects a type of white blood cell known as a lymphocyte. The specific type of lymphocyte that DLBCL affects is B cells, which serve to make antibodies to fight against pathogens.
A common treatment for DLBCL includes the use of a synthetic antibody called rituximab that destroys B cells, both normal and malignant. This process is called rituximab-mediated cellular cytotoxicity.